Know your target, know your molecule

May 15th, 2015 by Mark E Bunnage

Nature Chemical Biology 11, 368 (2015). doi:10.1038/nchembio.1813

Authors: Mark E Bunnage, Adam M Gilbert, Lyn H Jones & Erik C Hett

The pharmaceutical industry continues to experience significant attrition of drug candidates during phase 2 proof-of-concept clinical studies. We describe some questions about the characteristics of protein targets and small-molecule drugs that may be important to consider in drug-discovery projects and could improve prospects for future clinical success.